Result of concurrent chemoradiation with volumetric modulated arc therapy for non small cell lung cancer stage III patients

Nguyễn Lan Phương, Anh Tú Đỗ, Thanh Dương Phan, Công Định Đinh, Vũ Xuan Huy, Nguyễn Công Hoàng, Đỗ Tất Cương, Vinh Quang Bùi

Main Article Content

Abstract

Volumetric Modulated Arc Therapy – VMAT is an advanced technique which is applied widely among countries by the availability of multileaf collimators (MLC). With VMAT technique, series of small field shapes are created from each beam gantry. The relative weight of the dosage in each projection element will be optimized on each beam gantry. To perform this set up, we utilized directly the optimization of collimator aperture. The study aimed to assess the results and side effects of concurrent chemoradiation therapy by VMAT for treatment of non-small cell lung cancer stage III at K hospital. From June, 2017, we have implemented this technique to treat 30 NSCLC patients. The results showed that the VMAT dose-modulated radiotherapy technique had advantages over the 3D radiotherapy technique in the treatment plan as shown by the indexes of HI, CI, UI, V95 at PTV; V105, volume of organs receiving radiation dose; partial response rate accounted for 80%; The overall 24-month survival rate was 64%, and the rates of early and late complications including pneumonia and esophagitis were low and only at level 1 or 2.

Article Details

References

1. International Agency for Research on Cancer, World Health Organization. Globocan, Vietnam Fact Sheets Globocan 2018.; 2018. https://gco.iarc.fr/today/data/factsheets/populations/704 - viet - nam - fact - sheets.pdf,2018.
2. Anon. Dose Specification for Reporting External Beam Therapy with Photons and Electrons ICRU Report 29. United States: International Commission on Radiation Units and Measurements; 1987. http://inis.iaea.org/search/search.aspx?orig_q = RN:25005996.
3. Non - small Cell Lung Cancer Collaborative Group. Chemotherapy in non - small cell lung cancer: a meta - analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311(7010):899 - 909.
4. Wu VWC, Sham JST, Kwong DLW,. Inverse planning in three - dimensional conformal and intensity - modulated radiotherapy of mid - thoracic oesophageal cancer. Br J Radiol. 2004.
5. Jin X, Lin B, Chen D, et al. Safety and outcomes of volumetric modulated arc therapy in the treatment of patients with inoperable lung cancer. J Cancer. 2019;10(13):2868 - 2873. doi:10.7150/jca.31260
6. Liao ZX, Komaki RR, Thames HD, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non - small - cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(3):775 - 781. doi:10.1016/j.ijrobp.2009.02.032
7. Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperablestage IIIA or IIIB non - small cell lung cancer: Study CTRT 99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol. 2006;24:4397 - 4404.
8. Lee D - S, Kim Y - S, Kang J - H, et al. Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non - small Cell Lung Cancer. Cancer Res Treat. 2011;43(1):32 - 41. doi:10.4143/crt.2011.43.1.32